EWA
CRNX

EverSource Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

EverSource Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57K Sell
42
-55
-57% -$2.04K ﹤0.01% 3813
2026
Q1 		$3.52K Sell
97
-13
-12% -$581 ﹤0.01% 3422
2025
Q4 		$5.12K Buy
110
+43
+64% +$1.91K ﹤0.01% 3109
2025
Q3 		$2.79K Sell
67
-36
-35% -$1.15K ﹤0.01% 3402
2025
Q2 		$2.96K Buy
103
+32
+45% +$988 ﹤0.01% 3356
2025
Q1 		$2.38K Sell
71
-16
-18% -$598 ﹤0.01% 2849
2024
Q4 		$4.45K Buy
87
+10
+13% +$559 ﹤0.01% 2405
2024
Q3 		$3.93K Buy
77
+10
+15% +$516 ﹤0.01% 2323
2024
Q2 		$3.56K Buy
67
+33
+97% +$1.52K ﹤0.01% 2340
2024
Q1 		$1.49K Sell
34
-85
-71% -$3.33K ﹤0.01% 2463
2023
Q4 		$4.23K Buy
119
+78
+190% +$2.39K ﹤0.01% 1920
2023
Q3 		$1.22K Buy
+41
New +$845 ﹤0.01% 2144

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's CRNX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 57% in Q2 2026, selling an estimated $2.04K and leaving 42 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

EverSource Wealth Advisors first reported a position in CRNX in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.12K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • EverSource Wealth Advisors held 42 shares of Crinetics Pharmaceuticals worth $1.57K as of Q2 2026.
  • EverSource Wealth Advisors sold 55 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3813 holding.
  • EverSource Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • EverSource Wealth Advisors's Crinetics Pharmaceuticals position peaked at $5.12K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.